Methods of correction of hypogonadism syndrome in men and long-term results of drug treatment
Open Access
- 5 November 2025
- journal article
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 4 (3) , 12-19
Abstract
Hypogonadism syndrome, characterized by testosterone deficiency, negatively affects the physical, metabolic and psychoemotional health of men. The main treatments for hypogonadism include androgen replacement and androgen stimulating therapy. Androgen replacement therapy, represented by transdermal and injectable forms of testosterone, effectively restores testosterone levels, improves sexual function, muscle mass, bone mineral density and metabolic parameters. However, it suppresses spermatogenesis, which limits its use in men planning fatherhood. Androgen stimulating therapy, including gonadotropins, antiestrogens and aromatase inhibitors, stimulates the production of endogenous testosterone and spermatogenesis. Gonadotropins demonstrate high efficacy, but their long-term use is complicated by the need for frequent injections and the lack of long-term results. The long-term studies presented in the review confirm the safety and effectiveness of androgen replacement therapy, but data on androgen stimulating therapy are limited in follow-up time to a maximum of two years.Keywords
This publication has 42 references indexed in Scilit:
- Prostate Safety Events During Testosterone Replacement Therapy in Men With HypogonadismJAMA Network Open, 2023
- Skin Androgen-Related Disorders: Hormonal Treatment2023
- Testosterone Therapy: Transdermal Androgens2023
- Testosterone Therapy: Injectable Androgens2023
- The impact of long-term Testosterone Therapy (TTh) in renal function (RF) among hypogonadal men: An observational cohort studyAnnals of Medicine & Surgery, 2021
- Testosterone Therapy and Male Fertility2021
- The treatment of hypogonadism in men of reproductive ageFertility and Sterility, 2013
- Application of hormonal treatment in hypogonadotropic hypogonadism: more than ten years experienceInternational Urology and Nephrology, 2011
- The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile menFertility and Sterility, 2011
- Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA RecommendationsEuropean Urology, 2009